

**Diabetology for the Medical Oncologist: Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following drug types best reflects the mechanism of action of capivasertib?**
  - PARP inhibitor
  - CDK4/6 inhibitor
  - AKT inhibitor**
  - ESR1 inhibitor
- 2. In the CAPItello-291 study, what was the approximate median time to onset of all-grade hyperglycemia with the combination of capivasertib and fulvestrant?**
  - 3 days
  - 15 days**
  - 25 days
  - 40 days
- 3. Over time, the fasting glucose levels observed in patients receiving capivasertib/fulvestrant in the CAPItello-291 study ...**
  - Increased above normal range beginning on cycle 2 of treatment
  - Increased above normal beginning on cycle 2 of treatment and then decreased to within normal range
  - Remained within the normal range throughout treatment**
- 4. Which of the following agents does the American Diabetes Association recommend to be considered as first-line treatment of hyperglycemia due to treatment with PI3K alpha inhibitors?**
  - Insulin
  - Metformin**
  - GLP-1 receptor agonists
- 5. The Phase II METALLICA study evaluating prophylactic metformin before apelisib and endocrine therapy for patients with hormone receptor-positive, HER2-negative PIK3CA-mutated advanced breast cancer demonstrated which of the following outcomes among all patients over the first 8 weeks of treatment?**
  - Most patients developed Grade 3 or 4 hyperglycemia
  - About 25% of patients developed Grade 3 or 4 hyperglycemia
  - Fewer than 10% of patients developed Grade 3 or 4 hyperglycemia**